HRP20191432T1 - Sustav ekspresije i sekrecije - Google Patents

Sustav ekspresije i sekrecije Download PDF

Info

Publication number
HRP20191432T1
HRP20191432T1 HRP20191432T HRP20191432T1 HR P20191432 T1 HRP20191432 T1 HR P20191432T1 HR P20191432 T HRP20191432 T HR P20191432T HR P20191432 T1 HRP20191432 T1 HR P20191432T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
seq
acid molecule
molecule according
polypeptide
Prior art date
Application number
Other languages
English (en)
Inventor
Devin Tesar
Chen Xiaocheng
Mark Dennis
Isidro Hotzel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20191432T1 publication Critical patent/HRP20191432T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/10—Vectors comprising a special origin of replication system multiple origins of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/80—Vectors comprising a special origin of replication system from vertebrates
    • C12N2820/85—Vectors comprising a special origin of replication system from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Claims (9)

1. Molekula nukleinske kiseline, naznačena time, da kodira prvi i drugi polipeptid, operativno povezana na signalnu sekvencu koja kodira mBiP, pri čemu: (a) prvi polipeptid obuhvaća domenu varijabilnog teškog lanca (VH) koja obuhvaća VH-HVR1, VH-HVR2 te VH-VHR3; (b) drugi polipeptid obuhvaća domenu varijabilnog lakog lanca (VL) koja se sastoji od VL-HVR1, VL-HVR2 te VH-HVR3; (c) signalna sekvenca kodirana je sekvencom nukleinske kiseline koja kodira za aminokiselinsku sekvencu koja sadrži SEKV. ID br. 3; (d) prvi polipeptid i drugi polipeptid tvore protutijelo, fragment protutijela ili Fab fragment; i (e) pritom se prvi i/ili drugi polipeptid, kada se eksprimira u prokariotskoj stanici, spaja s proteinom oblaganja odabranim iz skupine koja se sastoji od pI, pII, pIII, pIV, pV, pVI, pVII, pVIII, pIX i pX bakteriofaga M13, f1 ili fd, ili proteina adaptera odabranog iz grupe koja se sastoji od SEKV. ID brojeva: 6 i 7.
2. Molekula nukleinske kiseline prema patentnom zahtjevu 1, naznačena time, da su VL i VH povezani s Fc, oznakom i/ili markerom.
3. Molekula nukleinske kiseline prema patentnom zahtjevu 1 ili 2, naznačena time, da je VL povezan s oznakom te time, da je VH povezan s Fc.
4. Molekula nukleinske kiseline prema patentnim zahtjevima od 1 do 3, naznačena time, da nukleinska kiselina kodira protein oblaganja koji se nalazi unutar sintetičkog introna, pri čemu je nukleinska kiselina smještena između nukleinske kiseline koja kodira CH1 i nukleinske kiseline koja kodira spojnicu-Fc ili Fc.
5. Molekula nukleinske kiseline prema patentnom zahtjevu 4, naznačena time, da je sintetički intron smješten između nukleinske kiseline koja kodira za CH2 i CH3 domenu protutijela ili time, da je sintetički intron smješten između nukleinske kiseline koja kodira za spojnu regiju i domenu CH2 protutijela.
6. Molekula nukleinske kiseline prema patentnim zahtjevima od 1 do 5, naznačena time, da je signalna sekvenca kodirana sekvencom nukleinske kiseline odabrane iz skupine SEKV. ID br.: 11, SEKV. ID br.: 16, SEKV. ID br.: 17 i SEKV. ID br.: 18.
7. Vektor, naznačen time, da obuhvaća molekulu nukleinske kiseline prema bilo kojem od patentnih zahtjeva od 1 do 6.
8. Stanica domaćina, naznačena time, da je transformirana vektorom prema patentnom zahtjevu 7.
9. Postupak dobivanja protutijela, naznačen time, da obuhvaća kultiviranje stanice domaćina iz patentnog zahtjeva 8, na način da se eksprimira nukleinska kiselina.
HRP20191432 2012-07-05 2019-08-07 Sustav ekspresije i sekrecije HRP20191432T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261668397P 2012-07-05 2012-07-05
US201361852483P 2013-03-15 2013-03-15
US201361819063P 2013-05-03 2013-05-03
EP13736741.3A EP2870247B1 (en) 2012-07-05 2013-07-03 Expression and secretion system
PCT/US2013/049310 WO2014008391A1 (en) 2012-07-05 2013-07-03 Expression and secretion system

Publications (1)

Publication Number Publication Date
HRP20191432T1 true HRP20191432T1 (hr) 2019-11-01

Family

ID=48783388

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191432 HRP20191432T1 (hr) 2012-07-05 2019-08-07 Sustav ekspresije i sekrecije

Country Status (15)

Country Link
US (4) US9803191B2 (hr)
EP (2) EP2870247B1 (hr)
JP (4) JP6309518B2 (hr)
KR (1) KR20150030693A (hr)
CN (2) CN110042114A (hr)
BR (1) BR112015000125A2 (hr)
CA (2) CA2877009C (hr)
ES (1) ES2743401T3 (hr)
HK (1) HK1204479A1 (hr)
HR (1) HRP20191432T1 (hr)
MX (1) MX356162B (hr)
PL (1) PL2870247T3 (hr)
RU (1) RU2670491C2 (hr)
SI (1) SI2870247T1 (hr)
WO (1) WO2014008391A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110042114A (zh) * 2012-07-05 2019-07-23 弗·哈夫曼-拉罗切有限公司 表达和分泌***
CN104342453A (zh) * 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
CN106103476B (zh) 2013-12-24 2020-11-27 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
EP3164492B1 (en) 2014-07-03 2019-10-23 F. Hoffmann-La Roche AG Polypeptide expression systems
EP3259353A4 (en) * 2015-02-19 2018-10-10 Axiomx, Inc. Methods of identifying and validating affinity reagents
US9969792B2 (en) 2015-06-12 2018-05-15 Axiomx, Inc. Methods and compositions for producing a chimeric polypeptide
GB201617270D0 (en) 2016-10-11 2016-11-23 Argen-X N V And Fairjourney Biologics Triple vector for expressing antibody molecules in full therapeutic format
MA56102A (fr) 2019-06-07 2022-04-13 Argenx Bvba Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1194539A2 (en) * 1999-06-25 2002-04-10 Universität Zürich Hetero-associating coiled-coil peptides and screening method therefor
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING A POLYPEPTIDE
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
AU2002216762A1 (en) 2000-06-29 2002-01-14 University Of Connecticut Coiled-coil mediated heterodimerization functional interaction trap
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424602C (en) 2000-10-06 2012-09-18 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-producing cell
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ATE382053T1 (de) * 2001-08-27 2008-01-15 Genentech Inc System zur antikörperexpression und- synthese
US20050130124A1 (en) 2001-10-05 2005-06-16 Wiersma Erik J. Phagemid display system
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
JP4773947B2 (ja) * 2003-01-09 2011-09-14 マクロジェニクス，インコーポレーテッド 細菌細胞及び哺乳動物細胞における抗体発現のための二重発現ベクター系
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
DK1737962T3 (da) * 2004-03-24 2010-12-13 Domantis Ltd GAS1-universel leder
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007130520A2 (en) 2006-05-04 2007-11-15 Abmaxis Inc. Cross-species and multi-species display systems
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
SI2519543T1 (sl) * 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
CN110042114A (zh) 2012-07-05 2019-07-23 弗·哈夫曼-拉罗切有限公司 表达和分泌***

Also Published As

Publication number Publication date
US20140011981A1 (en) 2014-01-09
PL2870247T3 (pl) 2019-10-31
EP2870247A1 (en) 2015-05-13
RU2015103757A (ru) 2016-08-27
JP2015521852A (ja) 2015-08-03
CA2877009C (en) 2023-10-03
KR20150030693A (ko) 2015-03-20
JP2023029903A (ja) 2023-03-07
JP6795537B2 (ja) 2020-12-02
EP2870247B1 (en) 2019-06-26
JP2018126145A (ja) 2018-08-16
BR112015000125A2 (pt) 2018-09-04
HK1204479A1 (en) 2015-11-20
US20170369869A1 (en) 2017-12-28
MX356162B (es) 2018-05-16
WO2014008391A1 (en) 2014-01-09
CN110042114A (zh) 2019-07-23
US10633650B2 (en) 2020-04-28
CN104428416B (zh) 2019-01-29
US20200385704A1 (en) 2020-12-10
JP2021045139A (ja) 2021-03-25
EP3578660A1 (en) 2019-12-11
JP6309518B2 (ja) 2018-04-11
RU2670491C2 (ru) 2018-10-23
CA3188124A1 (en) 2014-01-09
CA2877009A1 (en) 2014-01-09
US9803191B2 (en) 2017-10-31
US20240043831A1 (en) 2024-02-08
SI2870247T1 (sl) 2019-10-30
ES2743401T3 (es) 2020-02-19
CN104428416A (zh) 2015-03-18
MX2014015521A (es) 2015-06-04

Similar Documents

Publication Publication Date Title
HRP20191432T1 (hr) Sustav ekspresije i sekrecije
HRP20201153T1 (hr) Pd-1 sredstva visokog afiniteta i načini uporabe
HRP20190897T1 (hr) Laki lanac humaniziranih miševa
Fujii et al. PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin
HRP20161531T1 (hr) Fc fuzijski proteini koji sadrže nove linkere ili aranžmane
HRP20191865T1 (hr) Novi heterodimerni proteini
HRP20210916T1 (hr) Miševi s ljudskim univerzalnim lakim lancem
HRP20191608T1 (hr) Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida
HRP20191409T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
HRP20191902T1 (hr) Antigeni virusa ljudske imunodeficijencije, vektori, pripravci, i postupci njihove upotrebe
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
AR077088A1 (es) Proteinas biespecificas de union a antigeno
HRP20180226T1 (hr) Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
HRP20220649T1 (hr) Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu
JP2015521852A5 (hr)
FI3665192T3 (fi) Muunneltuja transferriinireseptoria sitovia polypeptidejä
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
WO2009007244A3 (en) Replication deficient influenza virus for the expression of heterologous sequences
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
PH12017502080A1 (en) Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
MX2015007421A (es) Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas.
MY196874A (en) Humanized anti-basigin antibodies and the use thereof
EP2998401A3 (en) Plants having enhanced yield-related traits and a method for making the same
MX2013002137A (es) Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para prepararlas.
HRP20220884T1 (hr) Proteini specifični za baff i b7rp1 i njihova uporaba